Are lower MRPs on cancer drugs translating into affordable care?
Are lower MRPs on cancer drugs translating into affordable care?
- ✓Are lower MRPs on cancer drugs translating into affordable care?
- ✓Primary Authority: Official communique verified from The Hindu Health & Medical.
- ✓Civic Domain: Categorized under health public notices.
In a move to make cancer treatment more affordable, the National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% for 137 non-scheduled anti-cancer drugs, reducing the price of nearly 900 cancer medicine brands by up to 70%-93%.
However, for comprehensive cancer care in India, price regulation might not be enough. Are lower MRPs on cancer drugs translating into affordable care? Indu Bhushan and K.M. Gopakumar discuss the question in a conversation moderated by Bindu Shajan Perappadan.
Indu Bhushan is bureaucrat, economist and the first CEO of Ayushman Bharat; K.M. Gopakumar is legal adviser, senior researcher and public health expert
- •Aspirants and citizens are advised to monitor official notices and circulars issued by The Hindu Health & Medical.
- •Verify all prescribed eligibility criteria, cutoff dates, and authenticated document requirements prior to formal submissions.
- •Track connected examination timetables, vacancy advisories, and administrative gazettes on SuchnaSetu.
| Issuing Authority | The Hindu Health & Medical |
|---|---|
| Topic Category | HEALTH |
| Jurisdiction | All India / National |
| Publication Date | 5 November 2026 |